An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Therapeutic Solutions International (TSOI) reported encouraging preliminary results from a collaboration with the Veltmeyer Institute for Advanced Therapeutics. The trial focused on patients with neurodegenerative diseases like ALS and autism. One patient showed a significant increase in T-regulatory cells, rising from 47% to 77% after treatment. Another young patient diagnosed with autism began speaking for the first time following therapy. The company aims to make stem cell treatments accessible and emphasizes its commitment to following FDA regulations.
Positive
Significant increase in T-regulatory cells in ALS patient from 47% to 77% post-treatment.
Autistic patient began to speak after JadiCell infusion, marking a breakthrough.
Company emphasizes commitment to accessible and ethical stem cell therapies.
Negative
None.
Phase III Adult Stem Cell Company Reports Positive Data Through “Right to Try” Accelerated Access Collaboration
ELK CITY, Idaho--(BUSINESS WIRE)--
Therapeutic Solutions International (TSOI) announced today preliminary results of a collaboration with the Veltmeyer Institute for Advanced Therapeutics aimed at providing patients with protocols, products and cells, developed by the Company. As part of the collaboration, the Veltmeyer Institute provided an update on the first three patients treated.
“In patients with neurodegenerative diseases such as ALS (Amyotrophic lateral sclerosis), there is a correlation between survival and the number of T-regulatory cells that can actually produce nerve protective growth factors. In the case of our ALS patient, in addition to physical improvements, an increase in T-regulatory cells after stem cell therapy was observed at an astounding level from 47% pre-treatment to 77% post-JadiCell infusion treatment. Another case we treated was that of a 5 1/2-year-old boy diagnosed with autism who has literally not spoken a single word since birth. After JadiCell infusion, he is now actually talking for the first time in his life. Treatment of the schizophrenic patient demonstrated some degree of improvement,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and Founder of the Veltmeyer Institute.
“We are committed to taking our stem cell therapies through the normal regulatory processes with the FDA,” said Timothy Dixon, President, and CEO of the Company. “With that being said, as a corporation we have a moral and social responsibility to provide access to promising treatments as fast and ethically as possible. Therefore we are pleased to collaborate with the Veltmeyer Institute to make stem cell therapy affordable and accessible to the vast majority of people needing such treatment. If we can reach this goal, we will have made another gigantic stride toward healing people of some of the most destructive diseases to plague mankind.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
What are the preliminary results reported by Therapeutic Solutions International (TSOI)?
Therapeutic Solutions International (TSOI) reported positive preliminary results from a collaboration with the Veltmeyer Institute, showing significant health improvements in ALS and autism patients post-treatment.
How did the treatment affect the ALS patient in the TSOI collaboration?
The ALS patient experienced a remarkable increase in T-regulatory cells from 47% to 77% after JadiCell infusion, indicating potential treatment effectiveness.
What breakthrough was seen in the autistic patient treated by TSOI?
The autistic patient, who had not spoken before, began to talk for the first time after receiving JadiCell infusion therapy.
What is TSOI's commitment regarding stem cell therapy?
TSOI is committed to ensuring that their stem cell therapies go through proper FDA regulatory processes while also making them accessible and affordable to a wider audience.
